RESEARCH TRIANGLE PARK, N.C., Oct. 9, 2008 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) announced today the start of a Phase II proof-of-concept clinical trial to evaluate the safety and efficacy of senicapoc, the Company's novel orally available small molecule inhibitor of the KCa3.1 potassium ion channel, in patients with allergic asthma. Results from a preclinical study demonstrated the ability of senicapoc to reverse antigen-induced increases in airway resistance and airway hyper-reactivity. The objective of the current trial is to confirm these positive results in a clinical setting.
